Marrone Bio Innovations (MBII) Stock Price
Marrone Bio Innovations Price
Revenue has compounded at 25.3% per year over the past 11 years to 44.31 M USD. Marrone Bio Innovations's net margin stands at -37.4%, up from -170.2% several years earlier.
Marrone Bio Innovations stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Marrone Bio Innovations over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Marrone Bio Innovations stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Marrone Bio Innovations's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Marrone Bio Innovations Price |
|---|
Marrone Bio Innovations Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Marrone Bio Innovations Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 7.00 | 14.00 | 9.00 | 9.00 | 14.00 | 18.00 | 21.00 | 29.00 | – | 44.00 | 56.00 | 71.00 | 91.00 | 107.00 | 118.00 |
| 66.67 | 40.00 | 100.00 | -35.71 | – | 55.56 | 28.57 | 16.67 | 38.10 | – | – | 27.27 | 26.79 | 28.17 | 17.58 | 10.28 |
| 60.00 | 28.57 | 21.43 | 300.00 | 300.00 | 28.57 | 38.89 | 47.62 | 55.17 | – | 61.36 | 61.36 | 61.36 | 61.36 | 61.36 | 61.36 |
| 3.00 | 2.00 | 3.00 | 27.00 | 27.00 | 4.00 | 7.00 | 10.00 | 16.00 | 27.00 | 27.00 | 34.36 | 43.57 | 55.84 | 65.66 | 72.41 |
| -13.00 | -20.00 | -29.00 | -48.00 | -48.00 | -23.00 | -23.00 | -17.00 | -35.00 | 1.00 | -14.00 | -12.00 | -3.00 | -4.00 | -7.00 | – |
| -260.00 | -285.71 | -207.14 | -533.33 | -533.33 | -164.29 | -127.78 | -80.95 | -120.69 | – | -31.82 | -21.43 | -4.23 | -4.40 | -6.54 | – |
| -13.00 | -38.00 | -28.00 | -51.00 | -51.00 | -31.00 | -30.00 | -20.00 | -37.00 | – | -16.00 | -18.00 | -3.00 | -3.00 | -5.00 | -7.00 |
| 62.50 | 192.31 | -26.32 | 82.14 | – | -39.22 | -3.23 | -33.33 | 85.00 | – | – | 12.50 | -83.33 | – | 66.67 | 40.00 |
| 1.00 | 1.00 | 9.00 | 22.00 | 24.00 | 25.00 | 29.00 | 101.00 | 118.00 | 149.00 | 175.00 | 175.00 | 175.00 | 175.00 | 175.00 | 175.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Marrone Bio Innovations generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Marrone Bio Innovations retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Marrone Bio Innovations's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Marrone Bio Innovations has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Marrone Bio Innovations's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Marrone Bio Innovations stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Marrone Bio Innovations Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Marrone Bio Innovations business model & stock analysis
Marrone Bio Innovations SWOT Analysis
Strengths
Marrone Bio Innovations Inc has a strong portfolio of innovative and sustainable bio-based pest management and plant health products. This gives them a competitive advantage in the agriculture industry.
The company's products have been proven effective in controlling a wide range of pests and diseases, which boosts their credibility and customer trust.
Marrone Bio Innovations Inc has established strong partnerships with major agricultural companies, enabling them to access larger markets and distribution networks.
The company has a dedicated and experienced team of researchers and scientists who continually develop new and improved bio-based solutions, keeping them at the forefront of agricultural innovation.
Weaknesses
Marrone Bio Innovations Inc faces challenges in terms of limited financial resources compared to some of their larger competitors. This can hinder their ability to invest in extensive marketing campaigns or expand into new markets.
The company's customer base is currently concentrated in certain regions, which makes them vulnerable to economic fluctuations or changes in regulations specific to those regions.
Marrone Bio Innovations Inc may encounter difficulties in changing the mindset of traditional farmers who are accustomed to using conventional chemical-based products. This requires additional education and awareness efforts.
Opportunities
The global trend towards sustainable agriculture creates significant opportunities for Marrone Bio Innovations Inc, as their bio-based products align well with the growing demand for environmentally friendly solutions.
Increasing concerns related to the negative impacts of chemical pesticides on human health and the environment open doors for the company to gain market share by offering safer alternatives.
Expansion into emerging markets, particularly in developing countries, provides Marrone Bio Innovations Inc with the chance to tap into new customer bases and increase revenue streams.
Threats
The agricultural industry is subject to various unpredictable factors such as weather conditions, pests, and disease outbreaks. These external factors can significantly impact demand for Marrone Bio Innovations Inc's products.
The competitive landscape in the bio-based agriculture sector is evolving rapidly, with new entrants continuously emerging. This intensifies competition and may erode market share.
Changes in regulations and policies related to pesticide usage can pose challenges for Marrone Bio Innovations Inc, as compliance with evolving standards may require product reformulation or additional testing.
Marrone Bio Innovations Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Marrone Bio Innovations Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Marrone Bio Innovations historical P/E ratio, EBIT multiple, and P/S ratio
Marrone Bio Innovations annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Marrone Bio Innovations's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Marrone Bio Innovations's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Marrone Bio Innovations's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Marrone Bio Innovations shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Marrone Bio Innovations Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 9/22/2021 | Maintained | Buy | 52 | |
| 8/19/2021 | Maintained | Buy | 25 | |
| 2/11/2021 | Maintained | Buy | 25 | |
| 8/14/2020 | Maintained | Buy | 25 | |
| 7/28/2020 | Maintained | Buy | 63 | |
| 5/14/2020 | Maintained | Buy | 25 | |
| 11/23/2016 | Maintained | Hold | 56 | |
| 3/16/2016 | Maintained | Buy | 51 | |
| 5/20/2015 | Downgrade | BuyHold | 56 | |
| 9/4/2014 | Maintained | Buy | 57 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Marrone Bio Innovations Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/29/2022 | -0.04USD | - | 15.53 MUSD | - | 2022 Q3 |
| 8/15/2022 | -USD | - | 16.00 MUSD | - | 2022 Q2 |
| 5/11/2022 | -0.02USD | -0.04USD | 12.21 MUSD | - | 2022 Q1 |
| 11/10/2021 | -0.03USD | -0.03USD | 9.86 MUSD | - | 2021 Q3 |
| 8/16/2021 | -0.01USD | -0.02USD | 10.64 MUSD | - | 2021 Q2 |
| 5/13/2021 | -0.02USD | -0.02USD | 11.26 MUSD | - | 2021 Q1 |
| 11/9/2020 | -0.03USD | -0.04USD | 8.83 MUSD | - | 2020 Q3 |
| 8/10/2020 | -0.06USD | -0.03USD | 24.36 MUSD | - | 2020 Q2 |
| 5/11/2020 | -0.04USD | -0.05USD | 7.72 MUSD | - | 2020 Q1 |
| 3/12/2020 | -0.06USD | -0.08USD | 5.02 MUSD | - | 2019 Q4 |
Marrone Bio Innovations shareholder structure
| % | Name |
|---|---|
4.69771% | |
1.22112% | |
0.41070% | |
0.19790% | |
0.05939% | |
0.05617% |
Marrone Bio Innovations Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
46.20% | SEC ↗ | |
46.20% | SEC ↗ | |
14.61% | SEC ↗ | |
14.61% | SEC ↗ | |
14.56% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ |
Marrone Bio Innovations Executives and Management Board
15 members · avg. age 60 · 20 % women
Mr. Kevin Helash (56)
Chief Executive Officer, Director · since 2020
1.10 M USD
Management
Ms. Linda Moore (74)
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Mr. Timothy Johnson (64)
Vice President - Field Development and Technical Services
Mr. Ladon Johnson (60)
Interim Chief Financial Officer
Dr. Amit Vasavada (66)
Senior Vice President - Research and Development, Chief Technology Officer
Mr. Keith Pitts (57)
Senior Vice President - Regulatory and Government Affairs, Chief Sustainability Officer
Mr. Matti Tiainen (32)
Senior Vice President - International Sales
Board of Directors
Dr. Pamela Marrone (64)
Director · since 2006
Mr. Robert Woods (77)
Independent Chairman of the Board
Dr. Zachary Wochok (78)
Independent Director
Mr. Yogesh Mago (39)
Independent Director
Mr. Stuart Woolf (61)
Independent Director
Mr. Keith McGovern (55)
Independent Director
Marrone Bio Innovations Supply Chain
Marrone Bio Innovations Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.48 | 0.62 | 0.79 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | — | — | — | ||
| 2 | -0.66 | -0.76 | -0.53 | ||
| 3 | 0.77 | -0.21 | -0.34 | ||
| 4 | 0.89 | -0.18 | -0.33 | ||
| 5 | UPL | 0.47 | 0.57 | -0.27 |
Frequently asked questions about Marrone Bio Innovations
The business model of Marrone Bio Innovations Inc is focused on providing sustainable and environmentally friendly solutions for the agriculture and water treatment industries. Marrone Bio Innovations develops and manufactures bio-based products that protect crops from pests and diseases, improve plant health, and enhance water quality. Their products are derived from naturally occurring microorganisms, which provide effective and safe alternatives to traditional chemical-based pesticides. Marrone Bio Innovations' innovative and eco-friendly solutions aim to help farmers increase crop yields while minimizing environmental impacts.
Marrone Bio Innovations Inc is primarily active in the agriculture and biotechnology industries.
The main competitors of Marrone Bio Innovations Inc in the market include Syngenta AG, Bayer AG, BASF SE, and Corteva Agriscience.
Marrone Bio Innovations Inc is an innovative company that focuses on providing sustainable biological solutions for agriculture and water treatment. Founded in 2006, Marrone Bio Innovations has rapidly grown to become a global leader in the development and commercialization of environmentally friendly and effective biopesticides and plant health products. With a mission to improve the quality and quantity of global food and water supply, the company offers a wide range of natural products that help farmers protect their crops against pests, diseases, and weeds. Marrone Bio Innovations continues to revolutionize the agricultural industry with its cutting-edge technologies and commitment to sustainability.
Marrone Bio Innovations Inc has achieved several significant milestones. The company successfully launched numerous innovative and sustainable bio-based products, establishing a strong position in the agricultural industry. Marrone Bio Innovations Inc also expanded its global reach by establishing strategic partnerships and collaborations with key players in the market. Additionally, the company received various recognitions and awards for its contributions to sustainable agriculture and environmental stewardship. Marrone Bio Innovations Inc continues to drive advancements in biopesticides, biofertility products, and other bio-based solutions, aiming to revolutionize the way pest management and crop protection are approached in modern agriculture.
Marrone Bio Innovations Inc is primarily present in the United States, focusing on various regions within the country. With their headquarters in Davis, California, the company operates across different states, including key agricultural areas such as California's Central Valley and the Midwest. Marrone Bio Innovations Inc also has a presence in international markets, particularly in Europe, where they have established partnerships and distribution networks to expand their reach.
Marrone Bio Innovations Inc represents a commitment to sustainable and environmentally friendly solutions in the agricultural industry. The company focuses on developing and commercializing bio-based pest management and plant health products, aiming to improve crop yields while minimizing the use of synthetic chemicals. With a strong dedication to innovation, Marrone Bio Innovations Inc strives to provide effective and safe products that help farmers maintain healthy and profitable crops. The company's corporate philosophy revolves around sustainability, responsibility, and a dedication to creating a more sustainable and resilient agriculture system.
10 analysts currently rate the Marrone Bio Innovations stock: 7 recommend buying, 3 holding and 0 selling.
The Marrone Bio Innovations share (MBII) is listed on 1 stock exchanges, including: NASDAQ (MBII).
The company Marrone Bio Innovations Inc is a leading provider of biological solutions for agriculture and horticulture. The company specializes in the development and marketing of biological pesticides and fertilizers used in agriculture and horticulture. Marrone Bio Innovations' business model is based on the development and marketing of biological products that are safe, effective, and environmentally friendly. The company has divided its products into different categories to best meet the needs of its customers. The core areas of Marrone Bio Innovations are plant protection and fertilization. In the field of plant protection, the company offers a wide range of biological pesticides that combat harmful insects, fungi, and diseases that can affect crop yield and quality. Some of the most well-known products include Grandevo®, Regalia®, Venerate®, Majestene®, Stargus®, and Zequanox®. Marrone Bio Innovations also has a strong presence in the field of fertilization. The company offers biological fertilizers that enrich the soil naturally and support plant growth. Optimized nutrient supply is an important factor in increasing crop quality and yield. Some of the most well-known products include Haven®, Haven CX®, Haven SW®, Haven Pure®, Haven Topper®, and Stargus®. Another important area of Marrone Bio Innovations is the development of biological solutions for horticulture, including growth stimulants for use on lawns, biostimulants for use on ornamental plants, and biological pesticides for use in home gardens. Some of the most well-known products include Haven® for lawns and GardenShield® for ornamental plants. Marrone Bio Innovations has expanded its business model with a strong research and development department. The company continuously invests in the development of new biological products that meet the highest standards. It works closely with scientists, universities, and other experts. Overall, Marrone Bio Innovations has developed a business model based on the development and marketing of biological solutions for agriculture and horticulture. By dividing its products into different categories, the company is able to tailor its products to the needs of its customers. Marrone Bio Innovations focuses on quality and research, working closely with experts to meet the highest standards and offer innovative and environmentally friendly products to its customers.
The revenue cannot currently be calculated for Marrone Bio Innovations.
The profit cannot currently be calculated for Marrone Bio Innovations.
The P/E ratio cannot be calculated for Marrone Bio Innovations at the moment.
The P/S cannot be calculated for Marrone Bio Innovations currently.
The Eulerpool Quality Score for Marrone Bio Innovations is 3/10.
The ISIN of Marrone Bio Innovations is US57165B1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Marrone Bio Innovations is A1W30B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Marrone Bio Innovations is MBII. The ticker symbol is used to trade Marrone Bio Innovations shares on the stock exchange.
Marrone Bio Innovations is assigned to the 'Commodities' sector.
The dividends of Marrone Bio Innovations are distributed in USD.
Marrone Bio Innovations stock
Marrone Bio Innovations Peer Group
Marrone Bio Innovations Ticker
Marrone Bio Innovations FIGI
All fundamentals and in-depth analysis of Marrone Bio Innovations
Our stock analysis for Marrone Bio Innovations stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Marrone Bio Innovations. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.